Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder
- PMID: 15788101
- PMCID: PMC1079893
- DOI: 10.1186/1471-2490-5-4
Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder
Abstract
Background: Interstital cystitis is often treated with exogenous glycosaminoglycans such as heparin, chondroitin sulphate (Uracyst), hyaluronate (Cystistat) or the semi-synthetic pentosan polysulphate (Elmiron). The mechanism of action is presumed to be due to a coating of the bladder surface to replace the normally present chondroitin sulphate and heparan sulphate lost as a result of the disease. This study used fluorescent labelled chondroitin sulphate to track the distribution of glycosaminoglycans administered intravesically to mouse bladder that had been damaged on the surface.
Methods: The surfaces of mouse bladders were damaged by 3 mechanisms -- trypsin, 10 mM HCl, and protamine sulphate. Texas Red-labeled chondroitin sulphate was instilled into the bladders of animals with damaged bladders and controls instilled only with saline. Bladders were harvested, frozen, and sectioned for examination by fluorescence.
Results: The normal mouse bladder bound a very thin layer of the labelled chondroitin sulphate on the luminal surface. Trypsin- and HCl-damaged bladders bound the labelled chondroitin sulphate extensively on the surface with little penetration into the bladder muscle. Protamine produced less overt damage, and much less labelling was seen, presumably due to loss of the label as it complexed with the protamine intercalated into the bladder surface.
Conclusion: Glycosaminoglycan administered intravesically does bind to damaged bladder. Given that the changes seen following bladder damage resemble those seen naturally in interstitial cystitis, the mechanisms proposed for the action of these agents is consistent with a coating of damaged bladder.
Figures

Similar articles
-
Novel Application of T1ρ Magnetic Resonance Imaging for Noninvasive Assessment of Bladder Hyperpermeability Biomarkers: A Focus on Glycosaminoglycan Content.Neurourol Urodyn. 2025 Jun;44(5):1081-1089. doi: 10.1002/nau.70058. Epub 2025 May 4. Neurourol Urodyn. 2025. PMID: 40320728
-
Intravesical glycosaminoglycan replenishment with chondroitin sulphate in chronic forms of cystitis. A multi-national, multi-centre, prospective observational clinical trial.Arzneimittelforschung. 2008;58(7):328-35. doi: 10.1055/s-0031-1296515. Arzneimittelforschung. 2008. PMID: 18751498
-
In the absence of overt urothelial damage, chondroitinase ABC digestion of the GAG layer increases bladder permeability in ovariectomized female rats.Am J Physiol Renal Physiol. 2016 May 1;310(10):F1074-80. doi: 10.1152/ajprenal.00566.2015. Epub 2016 Feb 24. Am J Physiol Renal Physiol. 2016. PMID: 26911855 Free PMC article.
-
[Available evidence about efficacy of different restoring agents of glycosaminoglycans for intravesical use in interstitial cystitis].Actas Urol Esp. 2013 Feb;37(2):92-9. doi: 10.1016/j.acuro.2012.10.002. Epub 2012 Dec 20. Actas Urol Esp. 2013. PMID: 23260184 Review. Spanish.
-
Importance of pharmaceutical composition and evidence from clinical trials and pharmacological studies in determining effectiveness of chondroitin sulphate and other glycosaminoglycans: a critique.J Pharm Pharmacol. 2009 Oct;61(10):1263-70. doi: 10.1211/jpp/61.10.0001. J Pharm Pharmacol. 2009. PMID: 19814857 Review.
Cited by
-
Treatment approaches for painful bladder syndrome/interstitial cystitis.Drugs. 2007;67(2):215-35. doi: 10.2165/00003495-200767020-00004. Drugs. 2007. PMID: 17284085 Review.
-
Differentiation-induced uroplakin III expression promotes urothelial cell death in response to uropathogenic E. coli.Microbes Infect. 2009 Jan;11(1):57-65. doi: 10.1016/j.micinf.2008.10.008. Epub 2008 Nov 1. Microbes Infect. 2009. PMID: 19007907 Free PMC article.
-
Intravesical Glycosaminoglycan Replacement with Chondroitin Sulphate (Gepan(®) instill) in Patients with Chronic Radiotherapy- or Chemotherapy-Associated Cystitis.Clin Drug Investig. 2015 Aug;35(8):505-12. doi: 10.1007/s40261-015-0306-6. Clin Drug Investig. 2015. PMID: 26175064 Free PMC article.
-
Prophylactic vesical instillations with 0.2% chondroitin sulfate may reduce symptoms of acute radiation cystitis in patients undergoing radiotherapy for gynecological malignancies.Int Urogynecol J. 2011 Jun;22(6):725-30. doi: 10.1007/s00192-010-1357-0. Epub 2011 Mar 2. Int Urogynecol J. 2011. PMID: 21365332 Free PMC article. Clinical Trial.
-
MRI as a Tool to Assess Interstitial Cystitis Associated Bladder and Brain Pathologies.Diagnostics (Basel). 2021 Dec 8;11(12):2298. doi: 10.3390/diagnostics11122298. Diagnostics (Basel). 2021. PMID: 34943535 Free PMC article. Review.
References
-
- Sand PK. Chronic pain syndromes of gynecologic origin. J Reprod Med. 2004;49:230–234. - PubMed
-
- Elbadawi AE, Light JK. Distinctive ultrastructural pathology of nonulcerative interstitial cystitis: new observations and their potential significance in pathogenesis. Urol Int. 1996;56:137–162. - PubMed
-
- Keay SK, Szekely Z, Conrads TP, Veenstra TD, Barchi JJJ, Zhang CO, Koch KR, Michejda CJ. An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. Proc Natl Acad Sci U S A. 2004;101:11803–11808. doi: 10.1073/pnas.0404509101. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical